GW Pharmaceuticals Shares Jump Following Price Target Raise
In a note released Monday morning, Piper Jaffray made a big raise to the price target of GW Pharmaceuticals (NASDAQ: GWPH) from $97 to $147, citing the potential of GW's Epidiolex to treat epilepsy.
The analysts at Piper Jaffray say that the unique safety/CNS profile make the drug an attractive way to treat epilepsy.
Additionally, the analysts noted that they do not believe INSYS Therapeutics will be able to compete on price.
Following the note, shares of GW Pharmaceuticals are up over six percent in the pre-market.
Latest Ratings for GWPH
|Nov 2015||Roth Capital||Assumes||Buy|
|Aug 2015||Morgan Stanley||Initiates Coverage on||Overweight|
|Apr 2015||Leerink Swann||Maintains||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.